Pancreatic cancer treatment in Turkey: options, risks and cost ranges for international patients

Symptoms of pancreatic cancer

Important: the symptoms described below are non-specific. They are far more often caused by benign conditions, and a medical evaluation is needed to find the cause before pancreatic cancer is suspected.

Pancreatic cancer is often silent at first, making early diagnosis difficult. There is currently no routine screening test for the general population. Surveillance is considered only for people at high risk, such as those with a strong family history, certain inherited mutations or certain pancreatic cysts, and it is best organized by a specialized team.

When the disease is more advanced, warning signs are more likely to appear:

• Abdominal pain radiating to the back.
• Sudden weight loss or unexplained loss of appetite.
• Sudden onset of diabetes.
• Blood clots (thrombosis).
• Severe tiredness for no apparent reason.
• Jaundice (yellowing of the skin and eyes),which can appear earlier when the tumor is in the head of the pancreas because it blocks the bile duct.

According to American Cancer Society data, only about 17% of pancreatic cancers are diagnosed at a localized stage, and most are found when the disease has already spread locally or to other organs, when surgery is often no longer possible. If you have persistent symptoms, don't ignore them: see your doctor.

Diagnosis at an earlier stage gives more treatment options. If you or a loved one have any of these signs, see your doctor, who will assess your situation and decide which examinations are appropriate for you.

Risk factors for pancreatic cancer

Several factors increase the risk of developing pancreatic cancer, although having one does not mean you will develop the disease, and many people with the disease have none of them:

• Smoking, one of the main modifiable risk factors.
• Diabetes, particularly long-standing diabetes. A new onset of diabetes in an older adult can also be an early sign of the disease.
• Chronic pancreatitis (long-lasting inflammation of the pancreas),including when it is linked to heavy alcohol use.
• Obesity and an unbalanced lifestyle.
• Family history of pancreatic cancer, and inherited genetic mutations such as BRCA1, BRCA2 or Lynch syndrome.
• Pancreatic cysts of certain types, which need regular monitoring.
• Age: the risk increases as you get older.

If you have one or several of these factors, talk to your doctor about whether monitoring or genetic counseling is appropriate for you.

Pancreatic cancer treatment options in Turkey

Pancreatic cancer is a complex disease that requires a multidisciplinary treatment approach (surgeon, medical oncologist, radiation oncologist, gastroenterologist, radiologist and palliative care team). The treatment depends mainly on the stage: resectable, borderline resectable, locally advanced or metastatic. A cure is possible only in selected cases, mostly when the tumor can be completely removed. For other patients, treatment aims to slow the disease, relieve symptoms and maintain quality of life.

Chemotherapy and radiation therapy

Chemotherapy is the backbone of treatment at almost every stage. Radiation therapy has a more limited and selective role.

• Neoadjuvant chemotherapy: Given before surgery, mainly in borderline resectable disease (European guidelines recommend it in this situation),to treat the cancer early and increase the chance that surgery can remove it completely. For tumors that are clearly resectable, upfront surgery is usually preferred.
• Adjuvant chemotherapy: Given after surgery to reduce the risk of recurrence. For patients in good general condition, the modified FOLFIRINOX regimen is the preferred option in European guidelines; gemcitabine with capecitabine is an alternative for patients who cannot receive it, and gemcitabine or 5-fluorouracil alone is reserved for frail patients.
• Chemotherapy for metastatic disease: Used to slow the progression of the disease and relieve symptoms, with regimens such as FOLFIRINOX or gemcitabine with nab-paclitaxel chosen according to the patient's general health.

Radiation therapy, including stereotactic techniques such as CyberKnife, is used selectively, for example in some borderline resectable or locally advanced tumors, or to relieve pain. European guidelines advise against routine radiochemotherapy after surgery, and the evidence for its survival benefit in pancreatic cancer remains limited, so the decision is made case by case by the multidisciplinary team. Proton therapy is available in only a few centers worldwide and is not a standard treatment for pancreatic cancer.

Surgery for pancreatic cancer

Surgery is the only treatment that can offer a chance of cure, but it is possible in only about 15 to 20% of patients at the time of diagnosis, when the tumor is localized and has not invaded major blood vessels or spread to other organs. It is a major operation with significant risks, which are detailed below and will be discussed with you at length. Even after complete removal, the cancer comes back in many patients, which is why chemotherapy is usually added.

The two main surgical procedures are:

• Whipple surgery: Removal of the head of the pancreas together with the duodenum, the bile duct, the gallbladder and sometimes part of the stomach, to treat pancreatic head tumors.
• Total or distal pancreatectomy: Depending on the location and extent of the tumor, the body and tail of the pancreas, or the whole pancreas, are removed.

The surgical decision depends on the exact location of the tumor and on your general health. The operation is complex and requires a long recovery period.

Targeted therapies and immunotherapy: the hopes of tomorrow

In Turkey, as in other countries, some newer treatments offer additional options for selected pancreatic cancer patients:

• PARP inhibitors (olaparib): Used as maintenance treatment in metastatic pancreatic cancer with a germline BRCA mutation when the disease has not progressed after platinum-based chemotherapy. In the POLO trial (New England Journal of Medicine, 2019),olaparib delayed disease progression, but no improvement in overall survival was demonstrated.
• RAS inhibitors (daraxonrasib): Approved by the US FDA in August 2026 for metastatic disease after at least one previous treatment. See the FAQ below for details and limits of the available data.
• Immunotherapy: It has limited benefit in most pancreatic cancers. However, for the small minority of patients whose tumor has high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR),immune checkpoint inhibitors are a valid treatment option and can be effective, with lasting responses in some patients. Testing for these features is therefore important. Research continues on combinations aiming to extend the benefit to more patients.

These therapies aim to target cancer cells more specifically, although they can still cause side effects, and they only suit patients whose tumor has the right characteristics, which molecular testing helps to identify. Availability of each drug can differ from one country and one center to another, so ask your oncologist what is accessible for your situation.

Palliative treatments

Palliative (supportive) care aims to improve quality of life and manage symptoms, especially pain. It is not only for the end of life: it can be started alongside anticancer treatment, as soon as symptoms or distress appear, and in advanced stages it becomes the main focus of care.

Palliative treatments include:

• Pain relief: Medications and procedures such as nerve blocks (celiac plexus block) to relieve pain.
• Treatment of jaundice: By placing a biliary stent to unblock the bile ducts.
• Nutrition and digestion: Dietitian follow-up and, when the pancreas no longer produces enough digestive enzymes, pancreatic enzyme replacement to limit weight loss and digestive symptoms, with nutritional supplements if needed.
• Other symptoms: Treatment of nausea, digestive blockage, fatigue and emotional distress, with support for the patient and family.

What factors affect prognosis?

The prognosis is based on the following factors

• The possibility of surgery: If the tumor is localized and can be removed surgically, the chances of a cure are greatly improved. However, if the tumor is inoperable, treatment options are limited.
• Cancer stage: The size of the tumor and its spread to other organs or lymph nodes have a direct impact on prognosis. Early diagnosis, when the cancer is still localized, offers many more treatment options and a more favorable prognosis than in advanced stages.
• The patient's general health: A patient in good physical health is better able to withstand severe treatments such as surgery, chemotherapy, or radiation.
• Type of diagnosis: first episode or recurrence: A newly diagnosed pancreatic cancer generally offers more therapeutic options than a recurrence, which is often more resistant to treatment. Early detection helps to better manage the disease and increase the chances of cure.

Our specialized centers in Turkey therefore focus on advanced diagnostic techniques to optimize the chances of therapeutic success.

Risks of surgical treatment

Surgery is the only treatment that can offer a chance of cure for pancreatic cancer, but it is a major operation with a significant risk of complications, and it does not always solve the problem permanently. Only about 15 to 20% of patients can have surgery at the time of diagnosis, and even after complete removal the cancer comes back in many patients, which is why chemotherapy is usually added. In published series, complications occur in roughly 30 to 60% of patients after a Whipple procedure, and some are serious. Here are the most important risks to consider:

• Risk of death after surgery (perioperative mortality): Major pancreatic operations, especially the Whipple procedure, are among the most complex abdominal surgeries. In published series the risk of dying from complications is below 5% in high-volume referral centers (often around 2 to 5%) and is considerably higher in low-volume hospitals, which is why the experience of the surgical team matters. Your surgeon will explain it in the context of your age, general health and tumor.
• Recurrence of the cancer: this is a risk of surgery in itself, not only a complication, and it is why regular follow-up is needed. In the ESPAC-4 trial, estimated five-year survival after surgery followed by chemotherapy was 16.3% with gemcitabine alone and 28.8% with gemcitabine plus capecitabine (Lancet, 2017). In the PRODIGE 24 trial, which included patients in good general condition, five-year survival was 43.2% with modified FOLFIRINOX versus 31.4% with gemcitabine (JAMA Oncology, 2022). These figures come from clinical trials and do not apply to every patient: surgery does not guarantee a definitive cure.
• Bleeding, during or after the operation, and the possible need for a blood transfusion. Severe bleeding can require a second operation or a radiological procedure to stop it.
• Infection, especially of the wound or lungs, may occur, as can abscesses inside the abdomen and, in severe cases, a generalized infection (sepsis). Antibiotics are given to prevent or treat such infections, and drainage or another procedure is sometimes needed.
• General anesthesia: Risks include allergic reactions, breathing problems, heart rhythm problems, heart attack and stroke, and rarely life-threatening complications. They are higher in older patients and in those with heart or lung disease, which is why the anesthesiologist assesses you carefully before the operation.
• Blood clots in the legs (deep vein thrombosis) that can travel to the lungs (pulmonary embolism),a risk increased by cancer and by major surgery.
• Development of diabetes or steatorrhea (fat digestion disorders). After a Whipple procedure or a larger pancreatic resection, diabetes can develop, and pancreatic enzyme replacement is often needed to digest food properly.
• Formation of pancreatic fistulas (leakage of pancreatic fluid),one of the most important complications of this surgery: published series report rates ranging from about 5 to 30% depending on the definition used, the surgical technique and the patient, and the clinically significant forms are less frequent than the mildest ones. A pancreatic fistula can be serious: it can cause infection or abscesses, bleeding, and prolong the hospital stay, and it may require prolonged treatment, sometimes surgical, to control the infection and allow healing.
• Bile leakage or leakage at the new connections between the digestive organs, which can require further procedures or surgery.
• Delayed gastric emptying, causing nausea, vomiting and difficulty eating for a period after the operation.
• Loss of pancreatic function, resulting in impaired absorption of nutrients and weight loss.
• Intensive care, reoperation or prolonged hospitalization may be needed if serious complications occur.

The risk of complications and death is lower in centers and teams that perform many pancreatic operations each year. Before choosing where to be treated, ask the team how many pancreatic resections it performs per year, what its results are, and how it manages complications such as fistula, bleeding and infection.

Risks and side effects of the other treatments

Non-surgical treatments also carry risks and side effects, which your oncologist will explain to you before treatment and monitor throughout. They differ depending on the protocol:

• FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan and oxaliplatin):
  • Febrile neutropenia (fever with a drop in white blood cells) is a medical emergency requiring urgent hospital care. Growth factor injections and dose adjustments can reduce the risk.
  • Severe diarrhea can lead to dehydration and may require hospital care. Anti-diarrhea medication and hydration are started at the first signs, and the team must be informed promptly.
  • Mouth and digestive mucosal inflammation (mucositis),nausea and vomiting (managed with anti-nausea drugs),fatigue and hair thinning are common.
  • Peripheral neuropathy (numbness or tingling in the hands and feet, often triggered by cold) can last after treatment, and the dose may be reduced if it becomes disabling.
  • Rarely, 5-fluorouracil can cause chest pain from spasm of the heart arteries, which requires stopping the drug and immediate medical assessment.
• Gemcitabine with nab-paclitaxel:
  • Drops in white blood cells (risk of infection),red blood cells (anemia) and platelets (risk of bleeding),monitored by blood tests before each cycle, with dose delays or reductions when needed.
  • Peripheral neuropathy, fatigue, hair loss and fluid retention (swelling).
  • Pneumonitis (lung inflammation) is rare but can be serious: a new cough or breathlessness must be reported immediately.
• Gemcitabine alone: Drops in blood cell counts, flu-like symptoms, fatigue, skin rash and changes in liver tests.
• Blood clots (thrombosis): Pancreatic cancer and its treatment, including chemotherapy, significantly increase the risk of blood clots. Careful monitoring and preventive measures can be put in place.
• Radiation therapy:
  • Fatigue, nausea, vomiting, loss of appetite and skin reactions in the treated area are common during treatment and are managed with medication and nutritional support.
  • Because the pancreas is close to the stomach, duodenum and intestines, irritation or ulcers of these organs can occur and cause pain or bleeding. Acid-reducing medication is often given, and bleeding or black stools must be reported immediately.
  • Late effects such as narrowing of the digestive tract can appear months after treatment, which is why follow-up is necessary. Side effects can be stronger when radiation is combined with chemotherapy.
• Immunotherapy: In pancreatic cancer, immune checkpoint inhibitors are an option for the small minority of tumors with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR),for whom they can be effective. They can cause the immune system to attack healthy organs, leading to inflammation of the bowel, lungs, liver or thyroid, adrenal or pituitary gland problems, skin rashes, fatigue and infusion reactions, which require prompt treatment.
• PARP inhibitors (such as olaparib, used for tumors with BRCA mutations): Fatigue, nausea, vomiting, loss of appetite and diarrhea are common, and anemia or drops in other blood cells can require monitoring or transfusion. Rarely, serious blood disorders (myelodysplastic syndrome or leukemia) and lung inflammation can occur. These drugs can harm an unborn baby, so effective contraception is required.
• RAS inhibitors (such as daraxonrasib, approved for previously treated metastatic disease): Skin rash and mouth sores (stomatitis) are the most common side effects leading to dose reduction.
• Palliative procedures: A biliary stent used to treat jaundice can become blocked or infected (cholangitis),and may need to be replaced.

Most side effects can be managed with medication (for example anti-nausea drugs),nutritional support and dose adjustments. Tell your medical team promptly about fever, uncontrolled vomiting or diarrhea, bleeding, severe pain or breathing difficulty. Not every treatment suits every patient: your general health, organ function and tumor characteristics determine which options are appropriate for you.